Comparative Pharmacology
Head-to-head clinical analysis: LANTRISUL versus SYNERCID.
Head-to-head clinical analysis: LANTRISUL versus SYNERCID.
LANTRISUL vs SYNERCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lantrisul (sulfadimethoxine) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking folic acid synthesis and ultimately nucleic acid production in susceptible bacteria.
Synercid is a combination of two streptogramin antibiotics, quinupristin and dalfopristin, which bind to the 50S bacterial ribosome and inhibit protein synthesis. Quinupristin binds to the 23S rRNA near the peptidyl transferase center, while dalfopristin binds to a nearby site and enhances quinupristin's binding. The synergistic effect results in irreversible inhibition of bacterial protein synthesis.
Intravenous: 3 mg/kg every 8 hours for 14 days, then 5 mg/kg every 12 hours for 14 days; oral: 800 mg (10 mg/kg) twice daily after intravenous phase.
7.5 mg/kg IV every 8 hours, administered as a 60-minute infusion.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 16-20 h). This supports once-daily dosing; steady-state achieved after 3-4 days.
The terminal elimination half-life is approximately 0.85 hours for dalfopristin and 1.3 hours for quinupristin; however, the active metabolite of quinupristin has a half-life of about 3.5 hours, supporting twice-daily dosing.
Approximately 70% renal excretion as unchanged drug, 15% fecal elimination via biliary secretion, 10% metabolized to inactive glucuronide conjugate eliminated renally, 5% other minor pathways.
Primarily hepatic metabolism with biliary excretion; approximately 15% of the dalfopristin dose and 32% of the quinupristin dose are excreted unchanged in feces; renal excretion is minor (<5% for both components).
Category C
Category C
Antibiotic
Antibiotic